IRIS
MARABOTTO, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.794
Totale 6.794
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.794
Totale 6.794
Salva come PNG Salva come JPEG
Città #
Genova 5.006
Genoa 935
Rapallo 830
Bordighera 21
Vado Ligure 2
Totale 6.794
Salva come PNG Salva come JPEG
Nome #
Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers 164
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 158
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. 138
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 134
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 134
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 134
Advancements in the use of manometry and impedance testing for esophageal functional disorders 131
Measurement of oro-caecal transit time by magnetic resonance imaging. 128
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 125
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 124
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 123
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 121
A safety review of proton pump inhibitors to treat acid-related digestive diseases 120
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 117
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 115
Proton pump inhibitors: use and misuse in the clinical setting 113
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity 112
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 111
Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. 109
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 109
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. 108
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 108
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 107
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 103
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 102
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 101
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 99
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease 98
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 97
Optimal management of constipation associated with irritable bowel syndrome. 96
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD 96
The appropriate use of proton-pump inhibitors 96
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 95
The natural history of gastro-esophageal reflux disease: A comprehensive review 93
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 92
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 90
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis 90
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 89
Epidemiology and natural history of gastroesophageal reflux disease 88
Esophageal motility abnormalities in gastroesophageal reflux disease 88
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 85
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 84
null 83
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 82
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 81
Updates in the field of non-esophageal gastroesophageal reflux disorder 80
Overweight is a risk factor for both erosive and non-erosive reflux disease. 80
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 78
Effects of bariatric surgery on the esophagus 78
Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. 76
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 75
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 73
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 71
Nonacid Reflux Is Able to Determine Microscopic Esophagitis in Non-Erosive Reflux Disease (NERD) Patients. 64
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication 64
The Lyon Consensus: Does it differ from the previous ones? 64
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 63
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 63
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 62
Vonoprazan fumarate for the management of acid-related diseases 61
Expression of Epidermal Growth Factor Receptor in patients with gastro-oesophageal reflux disease and in those with Systemic Sclerosis 55
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 52
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis 51
Presence of basal cell hyperplasia and dilatation of intercellular spaces and their association with baseline impedance values in patients with positive symptom association despite normal acid exposure further supports their role in symptoms generation in NERD 50
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 50
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 50
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 46
Prevention Strategies for Esophageal Cancer—An Expert Review 43
Pharmacotherapies in eosinophilic esophagitis: state of the art 43
COVID‐19 and liver disease: not all evil comes to harm 40
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 40
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring 37
Diabetes Medications and Risk of Hepatocellular Carcinoma 37
Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance 36
Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease 33
Sleeve gastrectomy may double the risk of esophageal adenocarcinoma in morbidly obese patients 33
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach 29
Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice 27
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 27
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience 26
Latest insights into the hot question of proton pump inhibitor safety – a narrative review 25
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 25
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 24
Complexity and diversity of gastroesophageal reflux disease phenotypes 24
Pharmacological management of gastro-esophageal reflux disease: An update of the state-of-the-art 24
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 21
European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic 21
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 21
Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply 18
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 18
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 17
Clopidogrel-Induced Eosinophilic Colitis 14
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review 11
Gastrointestinal Tract Cancers, an Increasing Burden of the Modern Era: Epidemiology and Prevention 10
Eosinophilic esophagitis and biologics 10
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes? 9
Food Intolerances, Food Allergies and IBS: Lights and Shadows 9
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 9
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 9
Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria 8
Totale 7.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.834
article - articoli 24.503
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 331
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.668
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.958 91 53 76 130 175 243 269 159 212 300 178 72
2020/2021944 43 81 68 118 56 88 41 124 76 105 66 78
2021/20221.036 102 27 67 95 33 104 32 229 66 121 36 124
2022/20231.013 105 100 19 87 177 131 6 85 177 5 110 11
2023/2024726 25 74 8 100 54 124 61 21 32 36 64 127
2024/2025107 107 0 0 0 0 0 0 0 0 0 0 0
Totale 7.109